Although the CRS is likely of higher grade in cancer patients with severe SARS-CoV-2 due to greater IL-6 production, the use of combination therapies offers a promising solution to mitigate the local and systemic nature of SARS-CoV-2 and its resulting cytokine production. This evidence concerns the gene IL6 and congenital rubella syndrome.